Mr. Don Cilla reports

APPILI THERAPEUTICS ANNOUNCES RESULTS OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

Appili Therapeutics Inc. has released the results from its annual and special meeting of shareholders, held earlier today.

Based on the proxies received and the vote conducted at the meeting, all tabled resolutions were approved by the shareholders of the company, including the election of the following directors for the ensuing year: Don Cilla, Brian Bloom, Theresa Matkovits, Juergen Froehlich, Armand Balboni and Prakash Gowd.

Voting results for each director are summarized in the attached table.

In addition to the election of the directors of the company as noted above, the shareholders:

• Approved the reappointment of PricewaterhouseCoopers LLP, chartered accountants, as the independent auditor of the company for the ensuing year and authorized the directors of the company to fix its remuneration;
• Approved unallocated options, rights or other entitlements under the company's rolling 10-per-cent stock option plan;
• Approved unallocated awards, rights or other entitlements under the company's equity incentive plan.

The company has filed a report of the voting results on all resolutions voted on the meeting on the company's SEDAR+ profile.

About Appili Therapeutics Inc.

Appili Therapeutics is a biopharmaceutical company that is purposefully built, portfolio driven and people focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili's goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The company is currently advancing a diverse range of anti-infectives, including a U.S. Food and Drug Administration-approved ready-made suspension of metronidazole for the treatment of anti-microbial resistant infections, a vaccine candidate to prevent tularemia, a serious biological weapon threat and a topical antiparasitic for the treatment of cutaneous leishmaniasis, a disfiguring disease. Led by a proven management team, Appili is at the centre of the global fight against infection.